Summary
Global Markets Direct’s, ‘Hypersensitivity - Pipeline Review, H1 2016’, provides an overview of the Hypersensitivity pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
- The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
- The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypersensitivity
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypersensitivity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Anacor Pharmaceuticals, Inc.
Eisai Co., Ltd.
Ensemble Therapeutics Corporation
F. Hoffmann-La Roche Ltd.
JW Pharmaceutical Corporation
Thesan Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypersensitivity Overview 6
Therapeutics Development 7
Pipeline Products for Hypersensitivity - Overview 7
Pipeline Products for Hypersensitivity - Comparative Analysis 8
Hypersensitivity - Therapeutics under Development by Companies 9
Hypersensitivity - Therapeutics under Investigation by Universities/Institutes 10
Hypersensitivity - Pipeline Products Glance 11
Early Stage Products 11
Hypersensitivity - Products under Development by Companies 12
Hypersensitivity - Products under Investigation by Universities/Institutes 13
Hypersensitivity - Companies Involved in Therapeutics Development 14
Anacor Pharmaceuticals, Inc. 14
Eisai Co., Ltd. 15
Ensemble Therapeutics Corporation 16
F. Hoffmann-La Roche Ltd. 17
JW Pharmaceutical Corporation 18
Thesan Pharmaceuticals, Inc. 19
Hypersensitivity - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
AN-3485 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ARN-077 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BD-750 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CWF-0808 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
E-34935 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
E-35018 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OA-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Recombinant Peptide to Inhibit Calcineurin for Rheumatoid Arthritis and Hypersensitivity - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RN-486 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Hypersensitivity - Dormant Projects 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41
List of Tables
Number of Products under Development for Hypersensitivity, H1 2016 7
Number of Products under Development for Hypersensitivity - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Products under Investigation by Universities/Institutes, H1 2016 13
Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 14
Hypersensitivity - Pipeline by Eisai Co., Ltd., H1 2016 15
Hypersensitivity - Pipeline by Ensemble Therapeutics Corporation, H1 2016 16
Hypersensitivity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 17
Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H1 2016 18
Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 27
Hypersensitivity - Dormant Projects, H1 2016 39
List of Figures
Number of Products under Development for Hypersensitivity - Comparative Analysis, H1 2016 8
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Top 10 Targets, H1 2016 21
Number of Products by Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
